Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may sharpen endometrial cancer risk prediction

NCT ID NCT07746024

Diagnosis Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current staging system, researchers hope to better identify which patients are at higher risk and may need more intensive follow-up or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liquid biopsy (blood test for circulating tumor DNA and proteins)
What this could lead to
If successful, this could lead to a more precise way to predict endometrial cancer recurrence, helping tailor follow-up and treatment to each patient's risk.
What could go wrong
This is an observational study, so it won't directly test a new treatment. The results may not change practice immediately, and the accuracy of the blood test in real-world settings remains to be seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients affected by endometrial cancer (EC) who underwent radical surgery with no residual disease, with samples already collected in the Institutional Biobank (PHASE 1) or prospectively enrolled (PHASE 2).

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged 18 or older 2. Has a histologically confirmed new diagnosis of EC, regardless of histologic subtype or grade; 3. EC staged according to the 2023 FIGO classification, with complete molecular assessment; 4. Eligible for curative-intent debulking surgery with no residual disease at the end of surgery; 5. No history of other malignancies within the preceding 3 years, except for curatively treated cervical carcinoma in situ, basal cell carcinoma of the skin, or ductal carcinoma in situ of the breast; 6. For patients included in the prospective cohort, written informed consent will be obtained, whereas for those included in the retrospective cohort, reference will be made to Article 110-bis of the Italian Privacy Code Exclusion Criteria: 1. Has persistent, recurrent, or newly diagnosed metastatic EC that is not amenable to curative treatment; 2. HIV, HBV or HCV-infected participants; 3. Received prior systemic anticancer therapy; 4. Patients with synchronous cancers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli, IRCCS

    Roma, 00186, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.